Rafferty Asset Management
RYTM icon

Rafferty Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Rafferty Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.58M Sell
32,207
-17,898
-36% -$1.62M 0.01% 465
2026
Q1 		$4.36M Sell
50,105
-5,421
-10% -$527K 0.02% 434
2025
Q4 		$5.94M Sell
55,526
-208
-0.4% -$22.1K 0.02% 383
2025
Q3 		$5.63M Buy
55,734
+4,123
+8% +$383K 0.02% 401
2025
Q2 		$3.26M Sell
51,611
-6,121
-11% -$375K 0.01% 489
2025
Q1 		$3.06M Buy
57,732
+7,338
+15% +$407K 0.01% 473
2024
Q4 		$2.82M Sell
50,394
-14,182
-22% -$783K 0.01% 544
2024
Q3 		$3.38M Sell
64,576
-7,986
-11% -$383K 0.01% 500
2024
Q2 		$2.98M Sell
72,562
-146,095
-67% -$5.83M 0.01% 532
2024
Q1 		$9.47M Buy
218,657
+97,003
+80% +$4.25M 0.04% 281
2023
Q4 		$5.59M Sell
121,654
-41,150
-25% -$1.3M 0.02% 422
2023
Q3 		$3.73M Sell
162,804
-96,540
-37% -$2.16M 0.02% 463
2023
Q2 		$4.28M Buy
259,344
+4,134
+2% +$74.6K 0.02% 450
2023
Q1 		$4.55M Sell
255,210
-50,803
-17% -$1.28M 0.03% 402
2022
Q4 		$8.91M Buy
306,013
+43,725
+17% +$1.12M 0.07% 213
2022
Q3 		$6.43M Buy
+262,288
New +$4.88M 0.07% 261
2022
Q1 		– Sell
-111,594
Closed -$1.11M – 1313
2021
Q4 		$1.11M Buy
111,594
+28,740
+35% +$323K 0.01% 820
2021
Q3 		$1.08M Sell
82,854
-167
-0.2% -$2.55K 0.01% 791
2021
Q2 		$1.63M Sell
83,021
-38,646
-32% -$802K 0.01% 742
2021
Q1 		$2.59M Buy
121,667
+111,888
+1,144% +$3.25M 0.02% 559
2020
Q4 		$291K Sell
9,779
-902
-8% -$22.9K ﹤0.01% 824
2020
Q3 		$231K Buy
+10,681
New +$245K ﹤0.01% 892
2020
Q1 		– Sell
-20,847
Closed -$479K – 767
2019
Q4 		$479K Sell
20,847
-7,134
-25% -$158K 0.01% 694
2019
Q3 		$604K Buy
27,981
+10,794
+63% +$232K 0.01% 638
2019
Q2 		$378K Buy
17,187
+3,071
+22% +$77.6K 0.01% 728
2019
Q1 		$387K Buy
+14,116
New +$406K 0.01% 703

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rafferty Asset Management's RYTM Position: Q2 2026 in Review

Rafferty Asset Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 36% in Q2 2026, selling an estimated $1.62M and leaving 32,207 shares worth $3.58M. The position accounts for 0.01% of the portfolio, ranked #465.

Rafferty Asset Management first reported a position in RYTM in Q1 2019 and has held it in 26 quarters since. The position peaked at $9.47M in Q1 2024. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Rafferty Asset Management held 32,207 shares of Rhythm Pharmaceuticals worth $3.58M as of Q2 2026.
  • Rafferty Asset Management sold 17,898 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.62M.
  • Rhythm Pharmaceuticals made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #465 holding.
  • Rafferty Asset Management first reported a position in Rhythm Pharmaceuticals in Q1 2019 and has held it in 26 quarters since.
  • Rafferty Asset Management's Rhythm Pharmaceuticals position peaked at $9.47M in Q1 2024.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.